161 results about "Bladder cancer cell" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with bladder cancer. The biological compositions can be used to retard the growth of bladder cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention provides sgRNA and a gene vector for inhibiting bladder cancer by targeting human lncRNA-UCA1 and an application of the sgRNA; specifically, sgRNA sequences of an lncRNA-UCA1 gene and a PD-1 gene suitable for CRISPR-Cas9 targeted splicing are designed; by transforming plasmids of specific splicing lncRNA-UCA1 gene and CRISPR-Cas9 nuclease gene into human bladder cancer cells, the expression of the lncRNA-UCA1 gene drops so as to inhibit the growth of tumor cells; and the plasmid, together with a human PD-1 gene targeted knockout vector, is transformed into a humanized mouse model of bladder cancer transplanted tumor, so as to obviously inhibit the growth of tumors. According to the invention, the vector is simple in preparing steps, the sgRNA is good in targeting property and the CRISPR-Cas9 is high in knockout efficiency.

The invention provides an integrated detection method for separating, enriching and detecting an exosome. The method comprises the following steps: designing and assembling a dual-membrane filtration chip, constructing an ELISA detection standard curve, collecting a sample, injecting and washing, performing chip ELISA detection, and performing data processing analysis. The invention also provides an integrated detection chip for separating, enriching and detecting a urine exosome. A reaction system and the detection method of the present invention can be used for detecting the content of a urine sample of a bladder cancer patient and the exosome in a supernatant of a bladder cancer cell line nutrient solution. The detection chip has characteristic of high specificity, generates no influence or wound on human body, and the detection method does not require the expensive precision experiment apparatus (such as an ultra centrifuge and a fluorescence microscope), and has large application prospect.

The invention belongs to the field of three-dimensional tumor cell culture and particularly relates to a three-dimensional drug resistance model of a tumor cell chemotherapy drug and a construction method thereof. The three-dimensional drug resistance model is obtained by dropwise adding an alginate-bladder cancer cell suspension into a divalent / trivalent metal cation salt bath for chelation and preparing cell-loaded alginate gel microspheres for three-dimensional culture. The tumor cell mass obtained by three-dimensional culture has acquired chemotherapy drug resistance, has the performance that the activity of three-dimensional cells is remarkably higher than that of planar cells under the same drug concentration, meanwhile the expression level of an ABCG2 transporter is remarkably improved compared with the expression level of the planar cells, and the chemotherapy drug resistance cell model is successfully constructed. The anti-tumor drug high-throughput screening and evaluation model can be formed by adjusting three-dimensional culture conditions of the cells, meanwhile can also be used for researching the acquired drug resistance mechanism of clinical chemotherapy drugs of tumor cells and find the target of reversal of the clinical chemotherapy drug resistance of bladder cancer cells and has a good application value.

The invention belongs to the technical field of cell detection apparatus, and relates to a micro-fluidic chip used for simultaneous detection of bladder cancer cells, calculi, blood cells, and bacteria in urine. The micro-fluidic chip is composed of a lower sample channel layer and an upper pneumatic microvalve layer used for controlling on-off of sample channels; the lower sample channel layer is composed of an urine sample inlet, an urine sample main channel, and an urine sample outlet liquid storage tank; a plurality of detecting units, including an urinary calculi interception unit, an urinary bladder transitional epithelial cancer detection unit, an urinary bladder adenocarcinoma cell detection unit, an urinary bladder squamous carcinoma cell detection unit, a blood cell detection unit, and a bacterium detection unit , are arranged on the urine sample main channel; and the detecting units are connected in series, and are arranged in a circular symmetry manner. The micro-fluidic chip is high in specificity and sensitivity, can be used for determining that whether a patient suffers from bladder cancer and urinary tract symptoms just via detection on urine, and is a cheap high-efficiency urine detection tool.

The invention discloses a molecular marker for diagnosing and treating the bladder cancer, namely LncRNA DANCR, and also discloses application of the molecular marker to screening or preparation of reagents used for diagnosing the bladder cancer diagnosing, bladder cancer lymphatic metastasis, bladder cancer prognosis relapse or bladder cancer clinical stages and application of the molecular marker to screening or preparation of drugs used for treating the bladder cancer. It is found that the LncRNA DANCR has high expression in bladder cancer cases with lymphatic metastasis, has negative correlation with overall survival prognosis of a patient and is an independent indicator for diagnosing the bladder cancer and judging bladder cancer development and survival prognosis; silencing of the LncRNA DANCR can restrain in-vitro proliferation, cell migration and invasion and in-vivo tumor formation and lymphatic metastasis of bladder cancer cells. It is verified that the LncRNA DANCR is an important cancerigenic factor of the bladder cancer for the first time, and can be used as a molecular marker for bladder cancer prognosis diagnosis and a new target spot for treatment.

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention relates to photosensitizer sodium chlorophyllin derivatives and their preparation method and novel use in preparation of drugs for treating tumors and especially in preparation of a photosensitizer drug for photodynamic treatment on the bladder cancer. The photosensitizer sodium chlorophyllin derivatives comprise sodium chlorophyllin e4, sodium chlorophyllin e6 and sodium chlorophyllin f compounds shown in the structural formula. An in-vitro human bladder cancer killing effect test on sodium chlorophyllin proves that the photosensitizer sodium chlorophyllin derivatives have obvious effects of killing tumor cells, good effects of treating bladder carcinoma in situ and intractable and repeated superficial bladder cancer, low toxicity and high safety, avoids operation in a dark place in treatment, has a unique advantage and provides an experiment basis for clinic application.

The invention discloses a bladder cancer screening detection kit which is capable of recognizing PVT1 genes specifically. The bladder cancer screening detection kit has the advantages that PVT1 is highly expressed in bladder cancer cells, and by means of detecting the PVT1 genes, early screening of the bladder cancer can be achieved; tetracycline-induced PVT1 shRNA (short hairpin ribonucleic acid) is capable of knocking out PVT1 expression effectively, inhibiting bladder cancer cell multiplication and promoting bladder cancer cell apoptosis so as to make bladder cancer diagnosis and treatment possible.

The invention provides application of target up-regulation PAR-4 gene small ribonucleic acid (RNA) in preparing bladder cancer resisting drugs. The nucleotide sequence of the target up-regulation PAR-4 gene small RNA is composed of six positive sense strands and negative sense strands of 21 nucleotides. The 3' end of each strand is provided with two nucleotides in suspension mode (generally dTdT, and the 19 nucleotides in the middle are paired.). The target up-regulation PAR-4 gene small RNA comprises sa RNA of different sequences. By means of expression of target up-regulation PAR-4 genes in the bladder cancer cells, the small RNA can restrain tumor cell activity, induces cell apoptosis, and further can be applied to preparation of bladder cancer resisting drugs. The application of target up-regulation PAR-4 gene small RNA in preparing the bladder cancer resisting drugs is simple in operation of preparing the small RNA, low in cost, small in using amount, capable of achieving good activation effect when the transfection concentration is 50nM and accurate in activation action. The mRNA and protein level of the target genes are both improved. In addition, the sa RNA can induce genes to express without damaging completeness of gene groups, thereby being safe to use.

The invention discloses 1, 5-diaryl-1, 2, 4-triazole compounds or pharmaceutically acceptable salts thereof shown as structural formula (I)-(III), and pharmaceutical compositions containing the compounds. The invention also discloses application of the compounds or pharmaceutically acceptable salts thereof in preparation of drugs for treatment of various malignant tumors and tumor metastasis related diseases. The compounds shown as formula (I)-(III) can realize concentration gradient dependent inhibition of the proliferation, invasion, infiltration and the like of breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells, bladder cancer cells and other tumor cells, have low toxicity, and have wide application prospects in bio-pharmaceutical industry.

The invention discloses an application of cedilanid in the preparation of anti-liver cancer and anti-bladder cancer medicaments; cedilanid is prepared into an injection, and is used for liver cancer and bladder cancer resistance; the concentration IC50 of the injection is 8*10-4 mmol / L. According to the invention, in an in-vitro experiment, the IC50 of cedilanid for liver cancer and bladder cancer cells is 8*10-4 mmol / L, and the effect is better than other cardiac glycoside medicaments; when compared with a common medicament of 5-fluorouracil with an IC50 of 1*10-1 mmol / L, cedilanid has a potency stronger by 100 times; in an antitumor experiment in animal body, cedilanid has a tumor inhibition rate of 34.26-48.43%; if application methods are proper, cedilanid is an ideal anticancer medicament.

The invention relates to a method for preparing the extract of corchorus capsularis seeds and the application of the extract. According to the method, corchorus capsularis seeds are crushed, and the petroleum ether 5 times the weight of corchorus capsularis seeds is added at the room temperature for extracting and degreasing. After the degreasing process, corchorus capsularis seeds are subjected to reflux extraction for 1-3 times in the ethanol aqueous solution 5-10 times the weight thereof, and the reflux extraction process lasts for 1-3 hours each time. The obtained extract is collected as the ethanol extract of corchorus capsularis seeds and is stored at 20 DEG C. The extract can be used for inhibiting the cell proliferation of human bladder cancer cells. Compared with the prior art, the extract is more efficient in growth proliferation effect for the human bladder cancer cell line T24 and has less influence on normal bladder epithelial cells. Therefore, the extract has an important significance on the treatment of bladder cancers, the comprehensive utilization of corchorus capsularis seed resources in China, and the increment of incomes for corchorus capsularis growers.

The invention belongs to the field of biotechnology, and specifically relates to miR-411 as a bladder cancer target and its application. The invention uses bladder cancer T24 and UMUC3 cells as models, and overexpressing miR-411 can inhibit the proliferation of bladder cancer cells in vivo and in vitro, and induce bladder cancer Cancer cell cycle G2 / M phase arrest, while enhancing the sensitivity of chemotherapy drugs (mitomycin and gemcitabine) to bladder cancer cells. It can be seen that miR-411 expression promoter can prevent or / and treat bladder cancer. Using miRNA chip technology, real-time fluorescent quantitative PCR technology, bioinformatics analysis of TCGA database and other methods to detect the expression of miR‑411 in bladder cancer primary animal models and clinical bladder cancer tissues showed a significant down-regulation trend, and the expression of miR‑411 was correlated with bladder cancer There is a certain positive correlation with the survival time of patients. It can be seen that by detecting the expression of miR‑411, bladder cancer can be assisted in the diagnosis and / or prognosis.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of bladder cancer cells and be used as a pharmaceutical composition to inhibit the bladder tumor growth.

Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. Also described is the determination of the difference between the rat neu oncogene and its corresponding proto-oncogene. Also described are nucleic acid probes reactive with regions of the proto-oncogene or oncogene, as are methods for their use in detecting the occurrence of the two types of genes. Antibodies specific for gene products encoded by the neu genes are also described, as are methods for their use.

The invention discloses an optically controlled gene expression device for highly-efficiently regulating tumor cell phenotype. The optically controlled gene expression device comprises a gene anchoring assembly, a transcriptional activation assembly, an sgRNA vector and a report / effect gene vector, wherein the gene anchoring assembly comprises a CIBN-dCas9-CIBN expression sequence represented by SEQ ID NO:4, the transcriptional activation comprises a CRY2PHR-P65 expression sequence represented by SEQ ID NO:7, the protein of the gene anchoring assembly is combined with a target sequence under the guidance of the sgRNA, and the CIBN-dCas9-CIBN is combined with the CRY2PHR-P65 under the irritation of blue lights to activate expression of report / effect gene. The optically controlled gene expression device can effectively drive expression of the report / effect gene in bladder cancer cells.

The invention relates to the field of immune analysis medicine, and particularly provides a kit for detecting human bladder cancer by a chemiluminescent analysis method on the basis of immune magnetic particles and a preparation method for the kit. According to the invention, the kit mainly comprises: 1) a bladder cancer EJ cell standard product; 2) magnetic particles which are coated by monoclonal antibodies capable of specifically identifying bladder cancer cell surface antigen; 3) enzyme-labeled monoclonal antibodies capable of specifically identifying bladder cancer cell surface antigen; 4) a chemiluminescent substrate which the enzyme in the 3) acts on; 5) a reaction tube or a microporous plate; and 6) a magnetic separator matched with the reaction tube or the microporous plate in the 5).

The invention provides application for directionally killing cisplatin-resistant human bladder cancer cells T24 / DDP through a coupling CD3*B7H3 dual-specificity antibody, particularly, the coupling CD3*B7H3 dual-specificity antibody can enhance the T24 / DDP cisplatin-resistant bladder cancer cell killing effect of the activated T cell (ATC), and an immunity treatment target spot is provided for bladder cancer drug-resistant targeting treatment. Researches prove that B7H3 can achieve high expression in the T24 / DDP cisplatin-resistant bladder cancer cell; compared with the ATC of the uncoupled CD3*B7H3 dual-specificity antibody, the capability of the ATC combined with the CD3*B7H3 dual-specificity antibody for directionally killing the T24 / DDP cisplatin-resistant bladder cancer cells is enhanced, and the remarkable cell toxin activity is achieved for the T24 / DDP cisplatin-resistant bladder cancer cells. When co-culture is performed on the condition that the effective target ratio of the ATC combined with the CD3*B7H3 dual-specificity antibody to the tumor cells is 10:1, the killing effect is remarkably increased. Meanwhile, the level of the ATC combined with the CD3*B7H3 dual-specificity antibody for secreting a gamma-interferon (IFN-gamma) and an alpha-tumor necrosis factor (TNF-alpha) is increased.

According to the technical scheme of an electrochemical bladder cancer DNA sensor, carboxylation is carried out on the surface of a glassy carbon electrode by an electrochemical method, and a bladder cancer cell specific DNA probe is assembled on the glassy carbon electrode to prepare the bladder cancer DNA sensor. The glassy carbon electrode is a base electrode, and electrode carboxylation and probe single-stranded DNA assembling are successively carried out. By electrode carboxylation, the probe DNA is fixed. The probe DNA is an recognition element, and a biological bridging agent is 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide and N-hydroxy succinimide. The preparation method is characterized in that the electrochemical bladder cancer DNA sensor with high sensitivity is obtained. The sensor has high sensitivity, high stability and good selectivity, and testing results of the sensor are better than those of a traditional DNA detection method. The preparation method comprises: 1, preparation of the electrochemical bladder cancer DNA sensor; 2, hybridization of the electrochemical bladder cancer DNA sensor and a target DNA; and 3, electrochemical signal detection of the sensor. The sensor has a simple operation method and is convenient for practical popularization and application.

The invention mainly belongs to the technical field of tumor immunology, and particularly relates to a human urinary bladder carcinoma marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71. The human urinary bladder carcinoma marker AG-CD71 provided by the invention is an abnormal glycosylated transferrin receptor TFRC; the abnormal glycosylated transferrin receptor TFRC refers tothat the TFRC carriers a saccharide structure Fucal-4(GlcNAcb1-3) as an epitope; the invention provides an antibody for the human urinary bladder carcinoma marker AG-CD71; the antibody is a specific monoclonal antibody ABC71 for preventing the human urinary bladder carcinoma marker AG-CD71; the monoclonal antibody is secreted from a hybridoma cell strain of which the preservation number is CGMCC No.14312. Cell and histology levels show that the ABC71 is capable of specifically recognizing human urinary bladder carcinoma cells and human urinary bladder carcinoma tissue. The monoclonal antibodyABC71 for preventing the human urinary bladder carcinoma has an intense positive reaction with human urinary bladder carcinoma tissue and has a negative reaction with normal human urinary bladder tissue.

The invention provides human bladder cancer cells capable of realizing multi-organ metastasis, and more specifically relates to a novel multi-organ metastasis bladder cancer cell line CH-2 which is preserved in China Center for Type Culture Collection (CCTCC) on August, 26th, 2013. Preservation number of the novel multi-organ metastasis bladder cancer cell line CH-2 is CCTCC No.C2013129. Cellular morphology and serial subcultivation characteristics of the novel multi-organ metastasis bladder cancer cell line CH-2 are stable; tumor forming performance is excellent; metastasis performance is high; the novel multi-organ metastasis bladder cancer cell line CH-2 can be used for generating high aggressive bladder cancer cells capable of realizing multi-organ metastasis, can be combined with low aggressive bladder cancer cell lines, and is used for selecting medicines used for treating bladder cancer with different characteristics, and selecting genes relating to metastasis.

The invention provides a single-stranded antibody fusion protein in growth factor receptors of human fibroblast cells. The single-stranded antibody fusion protein is an FGFR single-stranded antibody-alkaline polypeptide fusion protein, wherein the FGFR single-stranded antibody is the single-stranded antibody of FGFR1, 2, 3 or 4; and alkaline polypeptide is a polypeptide which comprises 9 to 30 alkaline amino acids. The invention further provides the application of the FGFR single-stranded antibody-alkaline polypeptide fusion protein in preparing targeting tumor cells medicines. In the application, the fusion protein is used as nucleic acid carriers to carry micro-molecules to disturb RNA (such as siRNA) to attack various tumor cells and tissues (such as leukemia stem cell, bladder cancer cell, breast cancer cell and the like) with high expression of FGFR correspondingly; and by inducing the tumor cells to die, restraining the growth and the division of the tumor cells and the like, the growth, the attack and the transference of the tumor cells are restrained at last.

A trans-epithelial appliance having a hemidesmosome formation-inducing protein composition derived from rat bladder carcinoma cells deposited thereon. This composition stimulates cell attachment and may be either the cell matrix or a soluble factor isolated from the conditioned medium. The appliance will be useful for diminishing inflammation and / or infection at the site of entry of the appliance. The appliance may also be used to stimulate gum junctional epithelium adhesion in the treatment of gingivitis and periodontitis. The composition may be used to maintain tissues ex vivo.

The invention relates to FGFR3 single-chain antibody-protamine fusion protein and an application thereof. The protein is prepared by the following steps: adding the gene sequence of truncated encoded protamine to the 3' end of a gene for coding the FGFR3 single-chain antibody so as to obtain a fusion gene; cloning the fusion gene to a prokaryotic expression vector and inducing expression in escherichia coli cells; and separating and purifying an inclusion body. The fusion protein can be used as a nucleic acid carrying tool so as to carry small interfering RNA (such as siRNA) to attack various corresponding FGFR3 high-expression tumor cells (such as leukemia stem cell, bladder cancer cell, breast cancer cell and the like); by inducing the apoptosis, growth inhibition, differentiation and the like of tumor cells, finally the effects of inhibiting the growth, invasion and metastasis of tumors can be achieved.

The invention belongs to the technical field of tumor biological gene therapy, and relates to a bladder cancer diagnosis and treatment biomarker and a target spot, in particular to application of circ-SLC38A1 as a target spot in a bladder cancer cell inhibition medicine. The invention discloses an expression condition of circ-SLC38A1 in tumor tissues of a bladder cancer patient and a function of circ-SLC38A1 in bladder cancer cells. It is found for the first time that circ-SLC38A1 can be used as a bladder cancer diagnosis biomarker and a drug therapy target. Compared with normal control, circ-SLC38A1 is significantly up-regulated in tumor tissues of bladder cancer patients. The result of the invention shows that interference on circ-SLC38A1 can inhibit the migration and invasion ability ofbladder cancer cells, and it is shown that the circ-SLC38A1 plays a role of a cancer-promoting gene in the occurrence and development of bladder cancer, and provides a new target for clinical treatment of bladder cancer.

The invention provides copy number amplification of the FRS2 gene, applications of the copy number amplification, and specific primer pairs for detecting the copy number amplification, and belongs tothe field of biotechnologies. The number of times for copy number amplification is 3 or more. The density of the new blood vessels in the bladder cancer sample after the copy number amplification is high. In the bladder cancer cell line cultured in vitro, specific siRNA is utilized for interfering the expression of FRS2, so that the capacity of recruiting the vascular endothelial cells of the bladder cancer cells and the capacity of inducing the vascular endothelial cells to form tubules of the bladder cancer cells are inhibited. The invention further provides the applications of the copy number amplification of the FRS2 gene in preparing kits for detecting bladder cancer. The technical scheme has the advantages that the copy number amplification can serve as one of biological detection indexes of a molecular probe or a targeting primer for developing the bladder cancer screening kit.

The invention relates to the technical field of biological medicines, and particularly discloses application of a circular RNAcirc0001610 and an expression product thereof in medicines for diagnosing and treating bladder cancer, and the nucleotide sequence of the circular RNAcirc0001610 is as shown in SEQ ID NO: 1. Experiments show that the expression of the circular RNAcirc0001610 and the expression product thereof in bladder cancer tissues is obviously up-regulated. In human bladder cancer cells 5637 and bladder cancer cells J82, the proliferation, migration and invasion levels of the bladder cancer cells are remarkably inhibited by knocking down the expression level of the circular RNAcirc0001610, that is, the growth of bladder cancer cell strains can be inhibited by down-regulating the expression of the circular RNAcirc0001610.

The invention discloses sialidase with metal ion tolerance, heat stability and acid stability. The amino acid sequence of the sialidase is as shown in SEQ ID No. 1 or is an amino acid sequence obtained through deletion and mutation of SEQ ID No. 1 and maintaining unchanged sialidase functions; and the amino acid sequence is purified after expression by Escherichia coli. The sialidase provided by the invention has strong tolerance to divalent metal ions, heat stability and acid stability, can hydrolyze substrates in the connection forms of alpha-2,3 and alpha-2,6 and realizes biotransformation of total gangliosides extracted from pig brains for preparation of high-purity GM1; meanwhile, it is found out for the first time that the sialidase can inhibit migration of bladder cancer cells by transforming ganglioside on the surface of the cancer cells into GM1, so the sialidase has important application prospects.